The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...
Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. A novel oral microtubule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback